Pulse Biosciences Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Paul LaViolette

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	n/a
Yönetim ortalama görev süresi	2.8yrs
Yönetim Kurulu ortalama görev süresi	7.2yrs

Son yönetim güncellemeleri

Recent updates

CEO

Paul LaViolette (66 yo)

no data

Görev süresi

Mr. Paul Arthur LaViolette is President, Chief Executive Officer, Principal Executive Officer and Principal Financial Officer at Pulse Biosciences, Inc. since January 9, 2025 and was its Independent Co-Cha...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Robert Duggan	Executive Co-Chairman	7.2yrs	US$257.41k	77.97% € 861.9m
Darrin Uecker	CTO & Director	2.3yrs	US$5.39m	0.25% € 2.7m
Mitchell Levinson	Chief Strategy Officer	3.4yrs	US$1.69m	0.23% € 2.5m
Kevin Danahy	Chief Commercial Officer & Principal Executive Officer	less than a year	US$5.86m	0.059% € 656.5k
Paul LaViolette	President	no data	Veri yok	Veri yok
Edison Manuel	Vice President of Operations	7.8yrs	Veri yok	Veri yok
Richard Nuccitelli	Chief Science Officer	10.2yrs	Veri yok	Veri yok
Kenneth B. Stratton	General Counsel & Corporate Secretary	3.7yrs	Veri yok	Veri yok
Patty Perla	Vice President of Human Resources	5yrs	Veri yok	Veri yok
David Danitz	Senior Vice President of Engineering	3.3yrs	Veri yok	Veri yok
Gansevoort Dunnington	Chief Medical Officer	1.7yrs	Veri yok	Veri yok
Niv Ad	Chief Science Officer of Cardiac Surgery	1.3yrs	Veri yok	Veri yok

2.8yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim: 6L8 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Robert Duggan	Executive Co-Chairman	7.2yrs	US$257.41k	77.97% € 861.9m
Darrin Uecker	CTO & Director	9.3yrs	US$5.39m	0.25% € 2.7m
Paul LaViolette	President	less than a year	Veri yok	Veri yok
Richard van den Broek	Independent Director	4.4yrs	US$208.89k	0% € 0
Mahkam Zanganeh	Independent Director	7.9yrs	US$173.00k	1.32% € 14.6m
Manmeet Soni	Lead Independent Director	7.2yrs	US$180.07k	0% € 0

7.2yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 6L8 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.2 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/01/23 00:32
Gün Sonu Hisse Fiyatı	2025/01/23 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Pulse Biosciences, Inc. 3 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Swayampakula Ramakanth	H.C. Wainwright & Co.
Anthony Vendetti	Maxim Group
Christopher Cooley	Stephens, Inc.

Pulse Biosciences Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Pulse Biosciences, Inc. Appoints Paul A. LaViolette as Chief Executive Officer

Pulse Biosciences, Inc. Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology

Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors

Shelley D. Spray Does Not Stand for Reelection from the Board of Pulse Biosciences, Inc

President & CEO recently bought €79k worth of stock

Pulse Biosciences, Inc Announces CEO Changes

Recent updates

Pulse Biosciences Announces Late-Breaking Data from its Nanosecond PFA 360° Cardiac Catheter System First-In-Human Feasibility Study Presented at the AF Symposium

Pulse Biosciences, Inc. Appoints Paul A. LaViolette as Chief Executive Officer

Pulse Biosciences, Inc. Announces Positive Clinical Data Presented At the American Thyroid Association

Pulse Biosciences, Inc. Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology

Pulse Biosciences, Inc. to Report Q3, 2024 Results on Oct 30, 2024

Pulse Biosciences, Inc. announced delayed 10-Q filing

Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors

Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System

Pulse Biosciences, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Pulse Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $60 million.

Pulse Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $60 million.

Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX® nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation

Pulse Biosciences, Inc.(NasdaqCM:PLSE) dropped from Russell Small Cap Comp Value Index

Shelley D. Spray Does Not Stand for Reelection from the Board of Pulse Biosciences, Inc

President & CEO recently bought €79k worth of stock

Pulse Biosciences, Inc Announces CEO Changes

Pulse Biosciences, Inc. Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System

New major risk - Financial position

New major risk - Financial position

Pulse Biosciences, Inc. to Report Q1, 2024 Results on May 07, 2024

Pulse Biosciences, Inc., Annual General Meeting, Jun 06, 2024

Pulse Biosciences, Inc. to Report Q4, 2023 Results on Mar 28, 2024

Pulse Biosciences, Inc. Announces FDA 510(K) Clearance for its CellFX nsPFA Percutaneous Electrode System

Pulse Biosciences Files 510(K) Submission with U.S. FDA for its CellFX nsPFA Cardiac Clamp

Pulse Biosciences, Inc. Announces First-In-Human Procedures with its Novel CellFX Nanosecond Pulsed Field Ablation Cardiac Catheter

Executive Chairman recently bought €1.0m worth of stock

Pulse Biosciences, Inc. Announces Filing of Premarket Notification 510(k) to U.S. Food and Drug Administration for its Novel CellFX nsPFA Percutaneous Electrode

Chief Strategy Officer recently bought €97k worth of stock

Pulse Biosciences, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Pulse Biosciences, Inc. Appoints Dr. Niv Ad as Chief Science Officer, Cardiac Surgery

New major risk - Revenue and earnings growth

Pulse Biosciences, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Pulse Biosciences, Inc. Appoints f Gansevoort 'Gan' Dunnington, M.D. as Its Chief Medical Officer

Pulse Biosciences, Inc. Announces Resignation of Sandra Gardiner as Chief Financial Officer

Pulse Biosciences, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Chief Strategy Officer & Director recently bought €72k worth of stock

Pulse Biosciences Announces Positive Clinical Data on Nano-Pulse Stimulation Procedure for Low-Risk Basal Cell Carcinoma Lesions

Pulse Biosciences, Inc. Announces FDA 510(k) Clearance for the Treatment of Sebaceous Hyperplasia

Pulse Biosciences, Inc. Announces Executive Changes

Pulse Biosciences, Inc. Receives FDA 510(K) Clearance of Expanded Energy Settings for Use with the CellFX System

Pulse Biosciences, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Pulse Biosciences, Inc.(NasdaqCM:PLSE) dropped from Russell 2000 Dynamic Index

Pulse Biosciences, Inc. has completed a Composite Units Offering in the amount of $15 million.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Pulse Biosciences, Inc

Pulse Biosciences, Inc., Annual General Meeting, May 19, 2022

Pulse Biosciences, Inc. to Report Q4, 2021 Results on Mar 31, 2022

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Pulse Biosciences, Inc

Pulse Biosciences Announces the Appointment of Kevin Danahy as Chief Commercial Officer

Pulse Biosciences, Inc Provides an Update on Recent FDA 510(k) Submission

Pulse Biosciences, Inc. Provides Revenue Guidance for the Fourth Quarter 2021

Forecast to breakeven in 2024

Independent Chairman of the Board recently bought €42m worth of stock

Pulse Biosciences, Inc. Announces First CellFX Procedure Performed in Canada

Pulse Biosciences Announces Health Canada Approval for CellFX® System

Pulse Biosciences® Presents Clinical Study Results of Nano-Pulse Stimulation™ Technology to Clear Benign Lesions at the American Society for Laser Medicine and Surgery (ASLMS) 2021 Virtual Annual Conference

Pulse Biosciences Announces First CellFX Procedures

Pulse Biosciences Announces Start of Controlled Launch of the CellFX System®

Pulse Biosciences, Inc. to Report Q4, 2020 Results on Feb 22, 2021

Pulse Biosciences, Inc. Announces FDA Clearance for the CellFX® System

New 90-day high: €23.60

Pulse Biosciences Updates on CellFX System Regulatory and Clinical Study Progress

New 90-day high: €19.30

New 90-day high: €15.20

Pulse Biosciences, Inc. to Report Q3, 2020 Results on Nov 09, 2020

Pulse Biosciences Announces Presentation of Clinical Results Using Nano-Pulse Stimulation Technology for the Clearance of Skin Lesions at the American Society for Dermatologic Surgery Virtual Annual Meeting

Pulse Biosciences, Inc. Announces FDA IDE Approval and Initiation of Sebaceous Hyperplasia Study

Pulse Biosciences, Inc. Announces the Company Is Not Reasonably Estimate the Future Impact to the Operations and Financial Results

CEO

Görev süresi